MidCap Financial Investment Corporation Reports Financial Results for the Quarter Ended September 30, 2025

MidCap Financial Investment Corporation Reports Financial Results for the Quarter Ended September 30, 2025 GlobeNewswire November 06, 2025 Results for the Quarter Ended September 30, 2025 and Other Recent Highlights: Net investment income per share for the quarter was $0.38, compared to $0.39 for the quarter ended June 30, 2025 Net asset value per share […]

OptimizeRx Reports Third Quarter 2025 Financial Results and Increases Fiscal Year 2025 Guidance

OptimizeRx Reports Third Quarter 2025 Financial Results and Increases Fiscal Year 2025 Guidance GlobeNewswire November 06, 2025 – Q3 revenue of $26.1 million, increased 22% year-over-year– Q3 gross profit increased 30% year-over-year to $17.5 million– Increases full year 2025 guidance to a revenue range between $105 million and $109 million and adjusted EBITDA range between

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire November 06, 2025 CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with

aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update

aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update GlobeNewswire November 06, 2025 Results reported for Phase 3 EFZO-FIT(TM) study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026. Company expects to complete enrollment in

Curis Provides Third Quarter 2025 Business Update

Management to host conference call and webcast today at 4:30 p.m. ET Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its financial and operating results for the third quarter ended September 30, 2025. https://mma.prnewswire.com/media/607886/Curis_Logo.jpg “We made good progress

Alkermes to Participate in Two Upcoming Investor Conferences

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. Stifel 2025 Healthcare ConferenceDate/Time: Thursday, Nov. 13, 2025 at 2:40 p.m. ET (7:40 p.m. GMT) Jefferies Global Healthcare Conference in LondonDate/Time: Wednesday, Nov. 19, 2025 at 11:30 a.m. ET (4:30 p.m. GMT) The live webcasts may be accessed under the

WF International Announces Closing of $3.44 Million Follow-on Public Offering

WF International Limited (the “Company” or “WF International”)(NASDAQ: WXM), an integrated electromechanical solutions company specializing in the supply, installation, fitting-out, and maintenance of HVAC systems, floor heating systems, and water purification systems, today announced the closing of its follow-on public offering of 1,720,688 units (the “Units”) at a public offering price of $2.00 per Unit.

KITS Eyecare Reports Record Third Quarter 2025 Results

Revenue Increased 25.1% Year-Over-Year to a Record $52.4 million Adjusted EBITDA of 5.5%, Improving Year-Over-Year to $2.9 million Net income of $1.9 million and $0.06 EPS Twelfth Consecutive Quarter Reporting Positive Adjusted EBITDA Kits Eyecare Ltd. (TSX: KITS) (“KITS” or the “Company”), a leading vertically integrated eyecare provider, is reporting its results for the third

TEDCO Announces Joint-Declaration Agreement Signing with Korea Venture Investment Corporation

The agreement will support collaborative efforts to expand the innovation ecosystem TEDCO, Maryland's economic engine for technology companies, announces a recent joint-declaration signing with South Korean entity, Korea Venture Investment Corporation (KVIC). KVIC's U.S. East Coast Office, located in New York City, supports Korean start-ups in gaining a global footprint and leading frontier technologies industries.

Scroll to Top